Crossmark

Successful treatment of osimertinib-resistant EGFR-mutant NSCLC with acquired BRAF V600E mutation using triple combination therapy: a case report with pathological confirmation

Crossref DOI link: https://doi.org/10.1186/s12957-025-04011-w

Published Online: 2025-10-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Lin, MingHui

Chen, XuYu

Lin, Fan

Yang, YanBo
License Information

Text and Data Mining valid from 2025-10-10

Version of Record valid from 2025-10-10
More Information

Article History

Received: 4 July 2025

Accepted: 6 September 2025

First Online: 10 October 2025

Declarations

:

: The Institutional Review Board (IRB) or equivalent ethics committee of the West China Xiamen Hospital of Sichuan University did not approve this study [Case Report Not required].

: The subject(s) provided informed written consent for the publication of the study data.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below